Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects

被引:16
|
作者
Theunissen, Peter T. [1 ,2 ,3 ]
Beken, Sonja [4 ]
Beyer, Bruce K. [5 ]
Breslin, William J. [6 ]
Cappon, Gregg D. [7 ]
Chen, Connie L. [8 ]
Chmielewski, Gary [9 ]
De Schaepdrijver, Luc [10 ]
Enright, Brian [11 ]
Foreman, Jennifer E. [12 ]
Harrouk, Wafa [13 ]
Hew, Kok-Wah [14 ]
Hoberman, Alan M. [15 ]
Hui, Julia Y. [16 ]
Knudsen, Thomas B. [17 ]
Laffan, Susan B. [18 ]
Makris, Susan L. [19 ]
Martin, Matt [17 ]
McNerney, Mary Ellen [20 ]
Siezen, Christine L. [2 ]
Stanislaus, Dinesh J. [18 ]
Stewart, Jane [21 ]
Thompson, Kary E. [20 ]
Tornesi, Belen [11 ]
Van der Laan, Jan Willem [1 ,2 ]
Weinbauer, Gerhard F. [22 ]
Wood, Sandra [23 ]
Piersma, Aldert H. [1 ,24 ]
机构
[1] Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, Bilthoven, Netherlands
[2] Med Evaluat Board, Graadt van Roggenweg 500, NL-3531 AH Utrecht, Netherlands
[3] Univ Appl Sci Utrecht HU, Innovat Testing Life Sci & Chem, Utrecht, Netherlands
[4] Fed Agcy Med & Hlth Prod, Brussels, Belgium
[5] Sanofi US Inc, Bridgewater, NJ USA
[6] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN USA
[7] Pfizer Worldwide Res & Dev, Groton, CT USA
[8] ILSI Hlth & Environm Sci Inst, Washington, DC USA
[9] Covance Labs Inc, Greenfield, IN USA
[10] Janssen R&D, Preclin Dev & Safety Beerse, Beerse, Belgium
[11] AbbVie Inc, N Chicago, IL USA
[12] ExxonMobil Biomed Sci Inc, Annandale, NJ USA
[13] US FDA, Silver Spring, MD USA
[14] Takeda Pharmaceut Co, Deerfield, IL USA
[15] Charles River Labs, Preclin Serv, Horsham, PA USA
[16] Celgene Corp, Summit, NJ USA
[17] US EPA, Natl Ctr Computat Toxicol, Res Triangle Pk, NC 27711 USA
[18] GlaxoSmithKline, Safety Assessment, King Of Prussia, PA USA
[19] US EPA, Natl Ctr Environm Assessment, Washington, DC 20460 USA
[20] Bristol Myers Squibb, Drug Safety Evaluat, New Brunswick, NJ USA
[21] AstraZeneca, Drug Safety & Metab, Macclesfield, Cheshire, England
[22] Covance Preclin Serv GmbH, Munster, Germany
[23] Merck Res Labs, Upper Gwynedd, PA USA
[24] Univ Utrecht, Inst Risk Assessment Sci, Fac Vet Sci, Utrecht, Netherlands
关键词
Pharmaceutical testing; embryo-fetal developmental toxicity; cross-species evaluation; non-clinical; IN-VITRO; THALIDOMIDE; ABNORMALITIES; ANIMALS;
D O I
10.1080/10408444.2016.1224807
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Regulatory non-clinical safety testing of human pharmaceuticals typically requires embryo-fetal developmental toxicity (EFDT) testing in two species (one rodent and one non-rodent). The question has been raised whether under some conditions EFDT testing could be limited to one species, or whether the testing in a second species could be decided on a case-by-case basis. As part of a consortium initiative, we built and queried a database of 379 compounds with EFDT studies (in both rat and rabbit animal models) conducted for marketed and non-marketed pharmaceuticals for their potential for adverse developmental and maternal outcomes, including EFDT incidence and the nature and severity of adverse findings. Manifestation of EFDT in either one or both species was demonstrated for 282 compounds (74%). EFDT was detected in only one species (rat or rabbit) in almost a third (31%, 118 compounds), with 58% (68 compounds) of rat studies and 42% (50 compounds) of rabbit studies identifying an EFDT signal. For 24 compounds (6%), fetal malformations were observed in one species (rat or rabbit) in the absence of any EFDT in the second species. In general, growth retardation, fetal variations, and malformations were more prominent in the rat, whereas embryo-fetal death was observed more often in the rabbit. Discordance across species may be attributed to factors such as maternal toxicity, study design differences, pharmacokinetic differences, and pharmacologic relevance of species. The current analysis suggests that in general both species are equally sensitive on the basis of an overall EFDT LOAEL comparison, but selective EFDT toxicity in one species is not uncommon. Also, there appear to be species differences in the prevalence of various EFDT manifestations (i.e. embryo-fetal death, growth retardation, and dysmorphogenesis) between rat and rabbit, suggesting that the use of both species has a higher probability of detecting developmental toxicants than either one alone.
引用
收藏
页码:900 / 910
页数:11
相关论文
共 38 条
  • [1] Comparing rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on systemic dose and developmental effects
    Theunissen, Peter T.
    Beken, Sonia
    Beyer, Bruce
    Breslin, William J.
    Cappon, Gregg D.
    Chen, Connie L.
    Chmielewski, Gary
    de Schaepdrijver, Luc
    Enright, Brian
    Foreman, Jennifer E.
    Harrouk, Wafa
    Hew, Kok-Wah
    Hoberman, Alan M.
    Hui, Julia Y.
    Knudsen, Thomas B.
    Laffan, Susan B.
    Makris, Susan L.
    Martin, Matthew
    McNerney, Mary Ellen
    Siezen, Christine L.
    Stanislaus, Dinesh J.
    Stewart, Jane
    Thompson, Kary E.
    Tornesi, Belen
    Van der Laan, Jan Willem
    Weinbauer, Gerhard F.
    Wood, Sandra
    Piersma, Aldert H.
    [J]. CRITICAL REVIEWS IN TOXICOLOGY, 2017, 47 (05) : 402 - 414
  • [2] Embryo-Fetal Developmental Toxicity Study Design for Pharmaceuticals
    Wise, L. David
    Buschmann, Jochen
    Feuston, Maureen H.
    Fisher, J. Edward
    Hew, Kok Wah
    Hoberman, Alan M.
    Lerman, Steven A.
    Ooshima, Yojiro
    Stump, Donald G.
    [J]. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2009, 86 (06) : 418 - 428
  • [3] Developmental toxicity of cysteamine in the rat: Effects on embryo-fetal development
    Beckman, DA
    Mullin, JJ
    Assadi, FK
    [J]. TERATOLOGY, 1998, 58 (3-4) : 96 - 102
  • [4] Embryo-fetal developmental toxicity study with kramecine in rat
    Cristobal-Luna, J. M.
    Paniagua-Castro, N.
    Escalona Cardoso, G. N.
    Perez-Gutierrez-Gonzalez, M. S.
    Alvarez, R. I.
    Madrigal-Bujaidar, E.
    Chamorro-Cevallos, G.
    [J]. TOXICOLOGY LETTERS, 2016, 259 : S195 - S195
  • [5] Alternative species and methods for embryo-fetal developmental toxicity studies for pharmaceuticals
    Pique, C.
    [J]. TOXICOLOGY LETTERS, 2019, 314 : S56 - S56
  • [6] Developmental toxicity of VPA in the rat: Effect on embryo-fetal development
    Gupta, Kiran
    Singh, K. P.
    [J]. NATIONAL ACADEMY SCIENCE LETTERS-INDIA, 2007, 30 (1-2): : 49 - 54
  • [7] Embryo-fetal developmental toxicity of carbamazepine administered orally in wistar rat
    Panda, Subham Kumar
    Kumar, Naveen H. M.
    Takawale, Pradeep
    [J]. REPRODUCTIVE TOXICOLOGY, 2024, 129
  • [8] Numeric Estimates of Teratogenic Severity from Embryo-Fetal Developmental Toxicity Studies
    Wise, L. David
    [J]. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2016, 107 (01) : 60 - 70
  • [9] Review of embryo-fetal developmental toxicity studies performed for recent FDA-approved pharmaceuticals
    Ishihara-Hattori, Kana
    Barrow, Paul
    [J]. REPRODUCTIVE TOXICOLOGY, 2016, 64 : 98 - 104
  • [10] Review of embryo-fetal developmental toxicity studies performed for pharmaceuticals approved by FDA in 2018 and 2019
    Barrow, Paul
    Clemann, Nicole
    [J]. REPRODUCTIVE TOXICOLOGY, 2021, 99 : 144 - 151